Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.70 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.70 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.61 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.94 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | CES1 | P23141 | 2/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PAM | P19021 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylacetic Acid SCHEMBL27387332 | 0.97 | AKR1B1 (0.90) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL28242469 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL1459 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL1330777 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL9449909 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL27758886 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL13618842 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL6597834 | 0.95 | AKR1B1 (0.85) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL11324907 | 0.95 | AKR1B1 (0.85) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL11772456 | 0.94 | AKR1B1 (0.94) | AKR1B1ABCC4LMNAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466251-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS INC. (US) | 2024-11-27 | — | — | EP | claimed |
| WO-2023134733-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-07-20 | — | — | WO | claimed |
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | claimed |
| JP-59073554-A | — | — | None | — | — | JP | disclosed |
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4574823-A1 | COMPOUNDS FOR INHIBITING OR DECOMPOSING CDK2 AND/OR CDK9, AND MEDICINAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-06-25 | — | — | EP | disclosed |
| CN-120051473-A | Compounds that inhibit or degrade CDK2 and/or CDK9 and medical uses thereof | 韩国化学研究院 | 2025-05-27 | — | — | CN | disclosed |
| US-20250101006-A1 | PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2025-03-27 | — | — | US | disclosed |
| EP-4472969-A1 | PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4466251-A1 | TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS | TECHFIELDS INC. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118871436-A | Synthesis of pyrazolyl derivatives useful as anticancer agents | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-4038247-A | STABILIZING POLYOLEFINS WITH DIACYL DIHYDRAZIDES | CIBA-GEIGY CORPORATION (US) | 1977-07-26 | — | — | US | disclosed |
| US-4015017-A | Certain biphenyl derivatives used to treat disorders caused by increased capillary permeability | LABORATOIRES PHARMASCIENCE (FR) | 1977-03-29 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-4012389-A | ANTICOAGULANTS | DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) | 1977-03-15 | — | — | US | disclosed |
| US-4002641-A | DIURETICS, SALURETICS, HYPOTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
| US-3966938-A | Treatment of thrombosis and the inhibition of blood platelet aggregation | SANDOZ LTD. (CH) | 1976-06-29 | — | — | US | disclosed |
| US-3965095-A | Oxindole derivatives | SANDOZ LTD. (CH) | 1976-06-22 | — | — | US | disclosed |
| US-3954754-A | ANTIHYPERTENSIVES | SANDOZ LTD. (CH) | 1976-05-04 | — | — | US | disclosed |
| US-3935214-A | ANTICOAGULANT | DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | CDK9, CDK20, CDK19 | GAA 1935/4885PTGS1 2204/4885CA2 1245/4885 |
| US-20250101006-A1 | PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | KRAS, NRAS, HRAS | GAA 3402/4885PTGS1 1790/4885CA2 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.